Clinical Trial Update: Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing AryoTrust, a trastuzumab biosimilar from AryoGen Pharmed, with Herceptin in breast cancer has completed and results were posted on 2024-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AryoTrust (trastuzumab (biosimilar))
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: AryoGen Pharmed Co. | Conditions: Malignant Neoplasm of Breast | Phase 3 | Status: COMPLETED | Results posted: 2024-06-28